MAR 31, 2019 07:30 PM PDT

Chemopreventative Drug Targets H. Pylori Infections

WRITTEN BY: Nouran Amin

A chemopreventative drug being tested for its ability to inhibit the production of cell growth in multiple types of cancer was found to act directly on the bacterium Helicobacter pylori (H. pylori)--specifically during the treatment process of preventing stomach cancer.

According to a study published in the Proceedings of the National Academy of Sciences, the chemopreventative drug--DFMO (difluoromethylornithine)—was found to reduce the virulent characteristics of an H. pylori infection which serves as the primary cause of gastric cancer, the third leading cause of cancer deaths worldwide.

The H. pylori bacterium infects roughly half of the human population, but only 1 percent of the infected individuals will develop stomach cancer. Although the infection is treatable for stomach cancer prevention, it is not exactly clear who can or can’t be treated. Additionally, the infection might actually incur beneficial effects as esophageal reflux diseases, asthma and other allergic disorders will occur more frequently in those infected with H. pylori.

Learn more about H. pylori infections:

"H. pylori has co-evolved with humans for at least 60,000 years, probably longer, and attempting to prevent stomach cancer by eliminating the infection with widespread use of antibiotics is not necessarily a good idea," said Keith Wilson, MD, Thomas F. Frist Sr. Professor of Medicine and professor of Pathology, Microbiology and Immunology. "Our study suggests that it might be possible to reduce the virulence of the bacteria, without having to eliminate it. It's a speculative and unusual way to think about an infection, but it could be an interesting strategy."

DFMO was demonstrated in H. pylori-infected animal models to inhibit an enzyme responsible for the production of polyamines, which are cell growth compounds implicated in the development of stomach cancer. These research findings are now the basis of an ongoing clinical trial where DFMO is being used for stomach cancer prevention in Honduras and Puerto Rico.

Source: Vanderbilt Medical University

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 26, 2018
Drug Discovery
DEC 26, 2018
New Blood Pressure Target
According to a study published in eLife, researchers concluded that a protein channel may serve as an effective target for blood pressure regulation. Targe...
DEC 27, 2018
Microbiology
DEC 27, 2018
Reputed Medicinal Soil Yields a Superbug-killing Bacterium
It's no secret that antibiotic resistance is a problem that already poses a serious threat to public health, and it's expected to get worse....
FEB 01, 2019
Drug Discovery
FEB 01, 2019
Statin Therapy Reduces Risk of Cardiovascular Complications Regardless of Age
A meta-analysis study, from randomized clinical trials, found that regardless of age, statin therapy is effective in decreasing the risk of developing vasc...
MAR 23, 2019
Drug Discovery
MAR 23, 2019
Bisphosphonates increasingly prescribed to the women most likely to benefit
Recently, there has been a trend in the age of women who have been prescribed bisphosphonates (BPs) for the treatment osteoporosis and the prevention of fr...
MAR 23, 2019
Drug Discovery
MAR 23, 2019
New Drug Therapeutic for Portal Hypertension
According to a study published in the journal of the American Gastroenterological Association, drug therapy, called sivelestat, may effectively treat life-...
MAR 24, 2019
Drug Discovery
MAR 24, 2019
Generic Weight Loss Drug Safe & Effective for Long-Term Use
In a study published in Obesity, an inexpensive weight-loss drug FDA-approved 60 years ago for a three month short-term use-- may now be regarded as safe a...
Loading Comments...